Pharmacogenomics Focus Cipherome specializes in software-based pharmacogenomics and bioinformatics to predict adverse drug reactions, presenting a clear value proposition for pharma, biotech, and clinical research organizations seeking safer drug development and personalized medicine solutions.

Platform Advantage The Xentinel platform combines personalized drug safety and biomarker discovery capabilities, offering a turnkey solution for ADR prediction and translational insights that can be monetized through partnerships, licensing, or software-as-a-service models.

Recognition Signals Recent finalist status in the AHA Health Tech Competition and participation at the AHA Scientific Session bolster credibility with cardiology-focused customers and health-tech buyers, suggesting timely outreach to pharma companies and academic medical centers exploring ADR risk tools.

Growth Readiness With a lean team (11-50 employees) and revenue in the low single-digit millions, Cipherome appears receptive to scalable partnerships, channel deals, and co-development opportunities with mid-market biotech startups and contract research organizations.

Funding & Ops modest funding level and existing cloud-based tech stack (AWS, Google Workspace, Webflow, etc.) indicate alignment with cloud-friendly, low-overhead deployment, enabling rapid pilots, proof-of-concept engagements, and low-friction evaluations for potential customers.